More on SHPGY

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings
- Holders

Financials

Income Statement
Balance Sheet
Cash Flow Statement

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

SHPGY Cash Flow Statement

Click line-items for a historical chart and %
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 204.8M
Share based compensation 55.7M
Gain on sale of non-current investments
Other
Movement in deferred taxes 25.3M
Equity in earnings of equity method investees -2.4M
Loss/(gain) on sale of product rights -40.2M
Changes in operating assets and liabilities:
Increase in accounts receivable -37.3M
Increase in sales deduction accrual 106M
Increase in inventory -11.7M
Increase in prepayments and other assets -137.5M
Decrease in accounts payable and other liabilities -145.1M
Net cash provided by operating activities 1.08B
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash -11.9M
Purchases of subsidiary undertakings, net of cash acquired -4.02B
Purchases of non-current investments -3.1M
Purchases of property, plant and equipment ("PP&E") -19.1M
Purchases of intangible assets
Proceeds from disposal of non-current investments, PP&E and product rights 8M
Returns of equity investments and proceeds from short term investments
Net cash used in investing activities -3.94B
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from drawings of revolving credit facility 2.31B
Repayment of debt acquired with ABH -1.25B
Payment under building finance obligation
Extinguishment of building finance obligation
Tax benefit of stock based compensation 29.1M
Proceeds from exercise of options
Payment of dividend -99.6M
Payments to acquire shares by ESOT
Net cash used in financing activities 773.3M
Net (decrease)/increase in cash and cash equivalents -2.09B
Effect of foreign exchange rate changes on cash and cash equivalents -1.1M
Cash and cash equivalents at beginning of period 2.24B
Cash and cash equivalents at end of period 153.6M
Supplemental information associated with continuing operations:
Interest paid -7.7M
Income taxes paid 82.9M
Non cash investing and financing activities:
Equity in Vertex Pharmaceuticals, Inc. ("Vertex") received as part consideration for disposal of non-current investment